Skip to main content

Advertisement

SpringerLink
Log in

Oncological safety of breast-conserving surgery after primary systemic chemotherapy in cT3–4 breast cancer patients

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to retrospectively assess the oncological safety of breast-conserving surgery (BCS) after primary systemic chemotherapy (PST) in terms of local recurrence (LR) in cT3–4 patients.

Methods

The subjects were 146 cT1–2 patients who underwent BCS after PST, and 169 patients with cT3–4 primary breast cancer. Of the 169 patients with cT3–4 disease, 20 underwent surgery first, and 149 underwent surgery after PST (mastectomy: 101 patients; BCS: 48 patients). The LR-free survival (LRFS) was analyzed using a Kaplan–Meier analysis. We evaluated the predictors using Cox proportional hazards modeling for LR after PST.

Results

There was no significant difference in 5-year LRFS between the cT1–2 and cT3–4 groups that underwent BCS after PST (98.6 vs. 92.5 %; P = 0.074). The 5-year LRFS was 94.7 % in the group that underwent initial surgery and 93.0 % in the PST group (P = 0.845) in the cT3–4 patients, while the 5-year LRFS rates were 93.2 % in the BCS subgroup and 92.5 % in the mastectomy subgroup (P = 0.958). In a multivariate analysis, the histological type, hormone negativity and a higher histological grade were independent predictors of LR after PST.

Conclusions

BCS after PST may be oncologically acceptable for cT3–4 breast cancers in terms of the LR compared with initial surgery or mastectomy after PST.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Takahashi H, Fujii T, Nakagawa S, Inoue Y, Akashi M, Toh U, et al. Usefulness of breast-conserving surgery for breast cancer. Surg Today. 2013;. doi:10.1007/s00595-013-0767-2.

    PubMed Central  Google Scholar 

  2. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600–8.

    Article  PubMed  Google Scholar 

  3. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999;10:47–52.

    Article  CAS  PubMed  Google Scholar 

  4. Broet P, Scholl SM, de la Rochefordiere A, Fourquet A, Moreau T, De Rycke Y, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat. 1999;58:151–6.

    Article  CAS  PubMed  Google Scholar 

  5. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.

    CAS  PubMed  Google Scholar 

  6. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998;9:1179–84.

    Article  CAS  PubMed  Google Scholar 

  7. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.

    Article  PubMed  Google Scholar 

  8. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814–9.

    Article  PubMed  Google Scholar 

  9. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004;22:2303–12.

    Article  PubMed  Google Scholar 

  10. Ishitobi M, Ohsumi S, Inaji H, Ohno S, Shigematsu H, Akiyama F, et al. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index. Cancer. 2012;118:4385–93.

    Article  PubMed  Google Scholar 

  11. Rouzier R, Pusztai L, Garbay JR, Delaloge S, Hunt KK, Hortobagyi GN, et al. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer. 2006;107:1459–66.

    Article  PubMed  Google Scholar 

  12. Loibl S, von Minckwitz G, Raab G, Blohmer JU, Dan Costa S, Gerber B, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13:1434–42.

    Article  PubMed  Google Scholar 

  13. Rouzier R, Extra JM, Carton M, Falcou MC, Vincent-Salomon A, Fourquet A, et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol. 2001;19:3828–35.

    CAS  PubMed  Google Scholar 

  14. Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30:3960–6.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Miles RC, Gullerud RE, Lohse CM, Jakub JW, Degnim AC, Boughey JC. Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age. Ann Surg Oncol. 2012;19:1153–9.

    Article  PubMed  Google Scholar 

  16. Tanioka M, Shimizu C, Yonemori K, Yoshimura K, Tamura K, Kouno T, et al. Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer. 2010;103:297–302.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Cebrecos I, Cordoba O, Deu J, Xercavins J, Rubio IT. Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy? Eur J Surg Oncol. 2010;36:528–34.

    Article  CAS  PubMed  Google Scholar 

  18. Ishitobi M, Komoike Y, Motomura K, Koyama H, Inaji H. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence. Breast J. 2010;16:9–13.

    Article  PubMed  Google Scholar 

  19. Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 2008;110:531–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Breast Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Kenjiro Jimbo, Takayuki Kinoshita, Sota Asaga & Takashi Hojo

Authors
  1. Kenjiro Jimbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takayuki Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sota Asaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Hojo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenjiro Jimbo.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jimbo, K., Kinoshita, T., Asaga, S. et al. Oncological safety of breast-conserving surgery after primary systemic chemotherapy in cT3–4 breast cancer patients. Surg Today 45, 1255–1262 (2015). https://doi.org/10.1007/s00595-014-1052-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-014-1052-8

Keywords

Search

Navigation